The project will combine Evaxion’s AI-Immunology platform with support from the Gates Foundation, it describes. Evaxion will deploy AI-Immunology to identify and combine various antigens to combat the virus. Based on these findings, a number of new antigen constructs will be designed for selection and validation.

“We are excited to apply our AI-Immunology platform to combat yet another infectious disease. The grant allows for further application and validation of our platform without adding to our operational spend,” says Christian Kanstrup, CEO of Evaxion.